<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02302547</url>
  </required_header>
  <id_info>
    <org_study_id>PHAO13-TP/TRULIGHT</org_study_id>
    <nct_id>NCT02302547</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy</brief_title>
  <acronym>TRULIGHT</acronym>
  <official_title>Randomized Clinical Trial to Evaluate the Interest of a Down-scaled Treatment Strategy Using Dual Therapy (Nucleoside Analogs) in HIV Infected Patients Already Being Treated Using Triple Therapy, Who Present With a Successful Virological Control and for Which the HIV Reservoir is Low to Moderate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HOSPITAL, ORLEANS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de La Rochelle</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HOSPITAL, SAINTES</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HOSPITAL, FOCH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HOSPITAL, CAEN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henri Mondor University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HOSPITAL, HOTEL DIEU</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HOSPITAL, CHARTRES</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HOSPITAL, SAINT LOUIS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tourcoing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital, NIORT</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tenon Hospital, Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the early 2000s, the &quot;TRILEGE©&quot; study was realized to determine if the reductive anti&#xD;
      retroviral strategy from an initial triple therapy (based on a protease inhibitor as the&#xD;
      third agent) towards a dual therapy of nucleoside analogs (in particular the association of&#xD;
      &quot;zidovudine +lamivudine&quot;) for patients infected by HIV and stabilized for at least 3 months&#xD;
      at a threshold value of 400 copies/ml, would allow to obtain a well-controlled plasmatic&#xD;
      viral load, with an aim to reduce the long-term side effects of the treatment.&#xD;
&#xD;
      The afore mentioned study showed that the reductive anti retroviral strategy was a failure.&#xD;
      No study has as yet to revaluate this strategy, in particular in the current context of&#xD;
      antiretroviral treatments.&#xD;
&#xD;
      Indeed, modern nucleoside inhibitors (Kivexa®, Truvada®) have extended half-lives as well as&#xD;
      a superior intrinsic power as compared to treatments proposed in the initial &quot;TRILEGE©&quot;&#xD;
      study. Furthermore, the better quality of current triple therapy (as compared to that used 10&#xD;
      years ago) has lead to substantial viral reservoir reduction.&#xD;
&#xD;
      Currently, a small number of patients is being successfully treated in the long-term (viral&#xD;
      load &lt; 20 copies/ml) using nucleoside analog dual therapy. The particular characteristics of&#xD;
      these patients have yet to be thoroughly investigated.&#xD;
&#xD;
      The patients concerned were all treated prematurely before ever passing below 200 lymphocytes&#xD;
      T CD4/mm3. It occurred that all these patients presented a low viral reservoir as measured by&#xD;
      HIV DNA quantification (&lt; 2,7 log copies/106 PBMC).&#xD;
&#xD;
      Therefore, by targeting patients who have (1) a strong immune restoration, (2) a low HIV DNA&#xD;
      value and (3) a very good observance, the investigators emit the hypothesis that, reductive&#xD;
      anti retroviral strategy that would consist in changing from a conventional triple therapy&#xD;
      towards a Nucleoside reverse-transcriptase inhibitors dual therapy, could allow for durable&#xD;
      control of viral replication with the concomitant benefice of reduced antiretroviral side&#xD;
      effects and cost.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">September 21, 2018</completion_date>
  <primary_completion_date type="Actual">August 23, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral Load at 48 weeks</measure>
    <time_frame>48 weeks</time_frame>
    <description>Percentage of patient having a viral load &lt; 50 copies/ml in each arm reductive anti retroviral strategy from an original backbone of 2 Nucleoside reverse transcriptase inhibitors (Tenofovir Disoproxil Fumarate+ Emtricitabine) coupled to a third agent, towards a therapeutic strategy containing the backbone therapy alone (Truvada®).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from week 4 in Viral load at 48 weeks</measure>
    <time_frame>between 4 weeks and 48 weeks</time_frame>
    <description>percentage of patients having a viral load between 50 and 400 copies/ml between week 4 and week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD 4 level in each arm</measure>
    <time_frame>48 weeks</time_frame>
    <description>delta CD 4 measurement in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from day 0 in HIV - DNA at week 48</measure>
    <time_frame>day 0 and 48 weeks</time_frame>
    <description>HIV DNA evolution between day 0 and week 48 in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RNA and DNA viral load (sub study)</measure>
    <time_frame>Time Frame: Week 24 to Week 48</time_frame>
    <description>RNA and DNA viral load in the genital tract (cervico-vaginal secretions or sperm): comparison between arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>triple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir Disoproxil Fumarate (nucleotide reverse transcriptase inhibitor) + Emtricitabine (nucleoside reverse transcriptase inhibitor) + third agent (boosted protease inhibitor or unboosted protease inhibitor or integrase inhibitor or celsentri or non-nucleoside reverse transcriptase inhibitor).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dual therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Truvada®&quot;245mg&quot;:oral administration Tenofovir Disoproxil Fumarate (nucleotide reverse transcriptase inhibitor) + Emtricitabine (nucleoside reverse transcriptase inhibitor)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triple therapy</intervention_name>
    <description>Dosage treatment and usual prescription</description>
    <arm_group_label>triple therapy</arm_group_label>
    <other_name>Tenofovir+Emtricitabine+Third agent (Including a non nucleoside reverse transcriptase inhibitor: efavirenz or nevirapine or etravirine or rilpivirine</other_name>
    <other_name>Tenofovir+Emtricitabine+Third agent (Including a ritonavir-boosted protease inhibitor : saquinavir or indinavir or fosamprenavir or tipranavir or darunavir or atazanavir or lopinavir</other_name>
    <other_name>Tenofovir+Emtricitabine+Third agent (Including an unboosted protease inhibitor: atazanavir or indinavir</other_name>
    <other_name>Tenofovir+Emtricitabine+Third agent (Including an integrase inhibitor raltegravir or dolutegravir or cobicistat-boosted elvitegravir</other_name>
    <other_name>Tenofovir+Emtricitabine+Third agent (Including a fusion inhibitor: enfuvirtide or a CCR5 antagonist :maraviroc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dual therapy</intervention_name>
    <description>1 tablet (200mg/245mg) daily for 48 weeks</description>
    <arm_group_label>dual therapy</arm_group_label>
    <other_name>Truvada®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-1 infected patient&#xD;
&#xD;
          -  Initial TT ARV started above (or equal to) 150 / mm3 LT CD4, and 18 months prior to&#xD;
             inclusion in the study&#xD;
&#xD;
          -  Ongoing antiretroviral therapy combining tenofovir + emtricitabine + a 3rd agent (IP /&#xD;
             r, IP, NNRTI, II, Inhibitors) with at least one undetectable viral load (CV &lt;50 copies&#xD;
             / mL) after introduction of the latter treatment.&#xD;
&#xD;
          -  Patient in virological success: CV &lt;50 copies / mL for at least 12 months, including&#xD;
             visit to selection.&#xD;
&#xD;
          -  Absence of previous therapeutic failure: no viral load ≥ 200 copies / mL (after 6&#xD;
             months of treatment) (Except in the case of a justified therapeutic interruption:&#xD;
             travel, stock-out ...) and of obtaining success Virologic after introduction of&#xD;
             treatment, without concept of genotypic resistance known to the ARVs used.&#xD;
&#xD;
          -  Cellular DNA-HIV &lt;2.7 log copies / 106 PBMC&#xD;
&#xD;
          -  Zenith RNA-HIV &lt;150,000 copies / ml (excluding viral load values during primary&#xD;
             infection if it is documented)&#xD;
&#xD;
          -  No genotypic resistance to currently used and known ARVs&#xD;
&#xD;
          -  Patient who has given written informed consent&#xD;
&#xD;
          -  Affiliate or beneficiary of a social security scheme&#xD;
&#xD;
          -  Patient followed on an outpatient basis, age ≥ 18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-compliant patient&#xD;
&#xD;
          -  Subject is pregnant, or lactating, or of childbearing potential and without&#xD;
             contraception&#xD;
&#xD;
          -  Active opportunistic infections&#xD;
&#xD;
          -  Major overweight (BMI ≥ 40)&#xD;
&#xD;
          -  Severe renal pathology (creatinine clearance &lt; 30ml/min)&#xD;
&#xD;
          -  Cirrhosis or severe liver failure (factor V &lt; 50%)&#xD;
&#xD;
          -  Prognosis threatened within 6 months&#xD;
&#xD;
          -  Circumstances that may impair judgment or understanding of the information given to&#xD;
             the patient&#xD;
&#xD;
          -  Malabsorption syndromes&#xD;
&#xD;
          -  The following laboratory criteria:&#xD;
&#xD;
               -  Serum ASAT,ALAT &gt; 5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Thrombocytopenia with platelet count &lt; 50.000/ml&#xD;
&#xD;
               -  Anemia with hemoglobin &lt; 8g/dl&#xD;
&#xD;
               -  Polynuclear neutrophil count &lt; 500/mm3&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LOUIS BERNARD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de TOURS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GWENAEL LE MOAL, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poitiers University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MARIAM RONCATO- SABERAN, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH de LA ROCHELLE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>THIERRY PASDELOUPS, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH de SAINTES</affiliation>
  </overall_official>
  <overall_official>
    <last_name>DAVID ZUCMAN, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL de FOCH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>RENAUD VERDON, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Caen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>SEBASTIEN GALLIEN, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU d'HENRI MONDOR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JEAN - PAUL VIARD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH d'HOTEL DIEU</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MARC LESTELLE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH de CHARTRES</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JEAN - MICHEL MOLINA, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT LOUIS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>FAÏZA AJANA, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH de TOURCOING</affiliation>
  </overall_official>
  <overall_official>
    <last_name>SIMON SUNDER, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH de NIORT</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilles PIALOUX, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL TENON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thierry MAY, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nancy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel ETIENNE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de ROUEN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unité des Maladies Infectieuses, CHU de CAEN</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses, CHR Orléans La Source, ORLEANS CEDEX 2</name>
      <address>
        <city>CHR d'ORLEANS</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Immunologie Clinique centre de Vaccination anti- VIH ANRS Hopital Henri- Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Interne et Maladies Infectieuses, Groupe Hospitalier La Rochelle, Cedex 01</name>
      <address>
        <city>La Rochelle</city>
        <zip>17019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie, centre Hospitalier Fontenoy, CH de CHARTRES</name>
      <address>
        <city>Le Coudray</city>
        <zip>28630</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de NANCY</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des maladies Infectieuses et tropicales, CH GEORGES RENON</name>
      <address>
        <city>Niort</city>
        <zip>79021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et tropicales, APHP SAINT LOUIS</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de diagnostic et thérapeutique, Hopital Hotel Dieu</name>
      <address>
        <city>Paris</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultation Maladies Infectieuses, Chu de Poitiers, Cedex</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maladies Infectieuses, CHU de ROUEN</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Interne, CH de SAINTONGE- BP 326</name>
      <address>
        <city>Saintes</city>
        <zip>17108</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Médecine Interne, Hôpital FOCH</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service Universitaire des Maladies Infectieuses et du Voyageur, CH DRON</name>
      <address>
        <city>Tourcoing</city>
        <zip>59200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Medecine Interne et Maladies Infectieuses, CHRU BRETONNEAU, TOURS CEDEX9</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 14, 2014</study_first_submitted>
  <study_first_submitted_qc>November 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2014</study_first_posted>
  <last_update_submitted>November 30, 2018</last_update_submitted>
  <last_update_submitted_qc>November 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-DNA</keyword>
  <keyword>dual therapy</keyword>
  <keyword>NRTI</keyword>
  <keyword>virological control</keyword>
  <keyword>truvada®</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Indinavir</mesh_term>
    <mesh_term>Saquinavir</mesh_term>
    <mesh_term>Fosamprenavir</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>Cobicistat</mesh_term>
    <mesh_term>Rilpivirine</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
    <mesh_term>Enfuvirtide</mesh_term>
    <mesh_term>Elvitegravir</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Etravirine</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Integrase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

